Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 19/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 19/20 | 1.00 |
| ▸ | CHRNG | P07510 | 18/20 | 1.00 |
| ▸ | CHRND | Q07001 | 18/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radafaxine SCHEMBL30486031 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29751668 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29465705 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453827 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL13014841 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL48964 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453734 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL14521595 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL5478077 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3154016 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1968603-A2 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | Algebra Inc. (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079470-A2 | THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS | ALGEBRA, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) | 2007-02-08 | — | — | US | claimed |
| EP-1678151-A1 | DIASTEREOMERIC DYNAMIC KINETIC RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL, SALTS, AND SOLVATES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1678152-A1 | ENZYME-CATALYZED DYNAMIC KINETIC RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL, SALTS, AND SOLVATES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1678150-A1 | NEW PROCESS FOR PREPARING AN OPTICALLY PURE 2-MORPHINOL DERIVATIVE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005044809-A1 | DIASTEREOMERIC DYNAMIC KINETIC RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL, SALTS, AND SOLVATES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2005042503-A1 | ENZYME-CATALYZED DYNAMIC KINETIC RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL, SALTS, AND SOLVATES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-12 | — | — | WO | claimed |
| WO-2005040140-A1 | NEW PROCESS FOR PREPARING AN OPTICALLY PURE 2-MORPHINOL DERIVATIVE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050096318-A1 | Pharmaceutically active morpholinol | GLAXOSMITHKLINE SPA (IT) | 2005-05-05 | — | — | US | claimed |
| US-6855820-B2 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-15 | — | — | US | claimed |
| US-20240366513-A1 | Methods For Administering Weight Loss Medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12048769-B2 | Methods for administering weight loss medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230301922-A1 | Layered Pharmaceutical Formulations | NALPROPION PHARMACEUTICALS LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20200352863-A1 | Methods For Administering Weight Loss Medications | Naipropion Pharmaceuticals LLC (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2001062257-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6274579-B1 | ANTIDEPRESSANTS, ANALGESICS; SEXUAL DISORDERS, ATTENTION DEFICIT DISORDER; DRUG ADDICTION; PARKINSON*S AND ALZHEIMER*S DISEASE; HEADACHES, OBESITY | GLAXO WELLCOME INC. | 2001-08-14 | — | — | US | disclosed |
| EP-1047428-A1 | PHARMACEUTICALLY ACTIVE MORPHOLINOL | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999037305-A1 | PHARMACEUTICALLY ACTIVE MORPHOLINOL | GLAXO GROUP LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096318-A1 | Pharmaceutically active morpholinol | ACHE, COMT, SNCA | CHRNB2 76/4885SLC6A2 70/4885CHRNB4 55/4885 |
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | METTL3, TPMT, MTAP | CHRNB2 2457/4885SLC6A2 236/4885CHRNB4 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.